Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer

Laetitia Huiart1,2,3*, Anne-Deborah Bouhnik2,3, Dominique Rey2,3,4, Frédérique Rousseau5, Frédérique Retornaz6, Mégane Meresse2,3, Marc Karim Bendiane2,3,4, Patrice Viens5,7, Roch Giorgi2,3,8

1 Unité de Soutien Méthodologique, CHU La Réunion, Saint-Denis, France, 2 U912 (SESTIM), INSERM, Marseille, France, 3 Université Aix Marseille, IRD, UMR-S912, Marseille, France, 4 ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d’Azur, Marseille, France, 5 Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France, 6 Centre Gériatralogique Départemental, Marseille, France, 7 Université Aix Marseille, Centre de Recherche en Cancérologie de Marseille, INSERM U891, Marseille, France, 8 Service Biostatistique et Technologies de l’Information et de la Communication, Hôpital de la Timone, Assistance Publique – Hôpitaux de Marseille, Marseille, France

Abstract

Purpose: Aromatase inhibitor therapy (AI) significantly improves survival in breast cancer patients. Little is known about adherence and persistence to aromatase inhibitors and about the causes of treatment discontinuation among older women.

Methods: We constituted a cohort of women over 65 receiving a first AI therapy for breast cancer between 2006 and 2008, and followed them until June 2011. Women were selected in the population-based French National Health Insurance databases, and data was collected on the basis of pharmacy refills, medical records and face-to-face interviews. Non-persistence to treatment was defined as the first treatment discontinuation lasting more than 3 consecutive months. Time to treatment discontinuation was studied using survival analysis techniques.

Results: Overall among the 382 selected women, non-persistence to treatment went from 8.7% (95%CI: 6.2–12.1) at 1 year, to 15.6% (95%CI: 12.2–19.8) at 2 years, 20.8% (95%CI: 16.7–25.6) at 3 years, and 24.7% (95%CI: 19.5–31.0) at 4 years. In the multivariate analysis on a sub-sample of 233 women with available data, women using complementary or alternative medicine (CAM) (HR = 3.2; 95%CI: 1.5–6.9) or suffering from comorbidities (HR = 2.2; 95%CI: 1.0–4.8) were more likely to discontinue their treatment, whereas women with polypharmacy (HR = 0.4; 95%CI: 0.2–0.91) were less likely to discontinue. In addition, 13% of the women with positive hormonal receptor status did not fill any prescription for anti-hormonal therapy.

Conclusion: AI therapy is discontinued prematurely in a substantial portion of older patients. Some patients may use CAM not as a complementary treatment, but as an alternative to conventional medicine. Improving patient-physician communication on the use of CAM may improve hormonal therapy adherence.

Citation: Huiart L, Bouhnik A-D, Rey D, Rousseau F, Retornaz F, et al. (2013) Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer. PLoS ONE 8(12): e81677. doi:10.1371/journal.pone.0081677

Editor: Junxuan Lu, Texas Tech Univ School of Pharmacy, United States of America

Received July 17, 2013; Accepted October 15, 2013; Published December 18, 2013

Copyright: © 2013 Huiart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was funded by the French Ministry of Research, the French National Institute of Cancer (INCa), regional authorities (Conseil Régional Provence-Alpes Côte-d’Azur), cancer foundations (Fondation de France and Association pour la Recherche sur le Cancer), and the National Institute for Health Research (UMR912 INSERM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: laetitia.huiart@mail.mcgill.ca

Introduction

In the field of oncology, the use of oral therapy is on the rise, and treatment adherence is under increasing scrutiny [1,2]. Oral adjuvant hormonal therapy in hormone-responsive early breast cancer (BC) reduces the risk of recurrence and increases survival rates [3]. Aromatase Inhibitors (AIs) were shown to improve disease-free survival as compared to tamoxifen in post-menopausal women [4,5,6,7,9]. They therefore constitute an alternative to adjuvant treatment of early BC [9,10].

Non-adherence and early discontinuation of hormonal treatment are likely to affect treatment efficacy in BC patients [3,11,12,13]. In a recently published meta-analysis on 29 observational studies, discontinuation rates for AIs ranged from 31 to 73% over the treatment period [14,15]. These heterogeneous results are derived either from pharmacy databases or from samples of limited size using self-reported measures of adherence. Studies on the determinants of non-adherence are therefore limited either by self-reported measures of adherence - known to largely overestimate adherence - or by access to a restricted
number of covariates in available pharmacy databases. While most database studies in pharmacoepidemiology use high quality pharmacy and medical data, they only rarely link these with medical records or with patient questionnaires. Combining data sources is necessary to improve our understanding of medication consumption patterns in conjunction with the patients’ broader environment [16].

Our objective was to combine multiple sources of data to obtain a description of adherence and persistence with AI treatment (along with their determinants) in a population-based cohort of post-menopausal women with primary BC. Specifically, we evaluated adherence to treatment based on drug delivery records in pharmacy databases, and took into account determinants not available in such databases by collecting longitudinal psychosocial data directly from the patient.

Methods

Primary data source

The primary data source for patient selection was provided by The French National Health Insurance System (NHIS). The NHIS delivers universal health coverage; hence its database is population-based, i.e. it covers all segments of the population. Data was obtained from the NHIS which provides health insurance to 98% of the French population. The study area comprised 3 French administrative districts (Alpes-Maritimes, Bouches-du-Rhone, Var), which correspond to a population of approximately 4 million inhabitants.

In France, hormonal therapy treatment is available only in pharmacy by medical prescription. Level of reimbursement varies according to drug and patient characteristics. BC patients are reported to the NHIS by their physician and receive all treatment free of charge. BC patients were identified through this medical registry that includes all patients eligible for full treatment coverage. This database can be linked to the pharmacy refill database thanks to a unique identifier allocated to every adult individual.

Detailed description of the NHIS database is provided elsewhere [17].

Study Population

The ELIPPSE 65 cohort was constituted in order to document the medium and long-term psychosocial impact of BC on women over 65. Eligible participants were women with a biopsy-proven diagnosis of primary BC who had been registered in the NHIS database between October 2006 and December 2008. Women were excluded if they had a previous history of BC; if they suffered from severe cognitive impairment, deafness or acute mental disorder; or if they were unable to answer a questionnaire. Follow-up was interrupted in June 2011.

We restricted the analysis to cohort members who received at least one supply of AI treatment for BC, as registered in the NHIS medication database.

Ethics statement

All participants provided a written informed consent to participate in the study. The study was approved by the French National Committee on Information Technology and Individual Liberties (CNIL).

Data Collection

Patient Data. In the month following BC diagnosis, all eligible women registered in the NHIS database were sent an explanatory letter about the survey by the NHIS medical advisory board and invited to return their written consent. Women who agreed to participate in the ELIPPSE 65 cohort were then sent a short self-administered questionnaire by mail, which included questions on patient characteristics and the circumstances of patient diagnosis. The follow-up comprised an in-home, face-to-face interview at 10 months. These interviews provided data on socio-demographic and psychosocial characteristics, physical activity, complementary and alternative medicine (CAM) use, medical follow-up, and a geriatric assessment conducted as part of this study.

The geriatric assessment focused on independent living skills with the Activities of Daily Living scale (ADL) [18], the Instrumental Activities of Daily Living scale (IADL) [19], and cognitive functions by the Mini-Cog [20]. Disability in the ADL/IADL scales was defined as the need for assistance in carrying out at least one activity mentioned in the corresponding scale.

Women were classified as having depressive symptoms if their GDS-15 score was 5 or higher [21].

Polypharmacy was defined as having concurrently 4 types of medication or more, as reported in the patient questionnaire.

Medical Record. In parallel, a medical record was obtained from the patient’s physician. A first medical questionnaire was sent to the physician who had established the diagnosis and/or who was in charge of cancer treatment. This questionnaire covered the patient’s medical history, concurrent diseases, pathological assessment of BC and detailed information on cancer treatment. Subsequent medical questionnaires were sent to the patient’s physician to obtain information on current treatment, BC recurrence, hospitalizations and vital status.

Pharmacy refill data. The NHIS pharmacy refill database was used to collect data on AI dispensed. All reimbursement claims are submitted to the NHIS at the moment of refill via a single electronic system. Drug characteristics, including name, dosage, and number of pills are recorded in the database. In France, AI are delivered free of charge for cancer patients. They are dispensed monthly even though a prescription may cover up to 3 months.

Definition of Medication Adherence and Persistence Measures

These 2 outcomes were defined from the pharmacy refill database. Adherence was measured by the Medication Possession Ratio (MPR) [22,23], which is defined as the number of days of treatment divided by the number of days between cohort entry and end of follow-up. For each woman, the number of days of treatment was calculated from the number of tablets dispensed combined with dosage instructions. Overlapping prescriptions were included in the calculation. Patients with an MPR below 80% were considered non-adherent [14,24,25,26].

We defined non-persistence to treatment as the first treatment discontinuation lasting more than 3 consecutive months.

Statistical Analysis

Descriptive statistics were computed for continuous data (mean, +/−standard deviation (sd) or median, 25–75% Inter Quartile Range (IQR)) and categorical data (sample size and percentage). Time to treatment discontinuation was calculated using Kaplan-Meier estimates to account for censored data. Women’s follow-up was censored at the time of death, BC recurrence or contralateral BC, switching to a different anti-hormonal treatment, or on June 2011, whichever came first. Results were expressed as cumulative probabilities of treatment discontinuation with 95% confidence intervals (CI). Kaplan-Meier estimates of treatment discontinuation of different sub-groups were compared using the log-rank test.
Independent predictors of AI discontinuation were identified using a Cox proportional hazards model. The proportional hazards assumption was checked by examining the log-minus-log survival plot drawn up for each cofactor. We included in the initial multivariate model variables with a \( p \)-value < 0.20 in the univariate analysis. We kept in the final model only variables that were still significantly associated with AI intake discontinuation with a \( p \)-value < 0.10.

Statistical analyses were performed using the STATA version 9.0 software program (STATA Corp, College Station, TX).

Results

From October 2006 to December 2008, 678 women over 65 with BC were included in the ELIPPSE 65 cohort. A prescription of AIs was filled at least once by 447 of these women (65.9%). Among the latter, 65 (14.5%) were found to be non-eligible (Figure 1). In short, 382 women were included in the cohort used to describe rates of non-persistence to AI therapy.

The 382 women included in the cohort were followed for a median period of 3.2 years (IQR = [2.6–3.9]). Among these women, 3 had a BC recurrence, 4 developed a new cancer and 8 died during follow-up.

Non-persistence to AI defined from the pharmacy refill database

In addition to the 382 women who filled at least one prescription of AI medication, 57 women (13%) included in the ELIPPSE 65 cohort had positive hormonal receptors but did not fill any prescription. As these women did not receive any supply of AI treatment for BC, they were not eligible for the current analysis. Overall, non-persistence went from 8.7% (95%CI: 6.2–12.1) at 1 year, to 15.6% (95%CI: 12.2–19.8) at 2 years, 20.8% (95%CI: 16.7–25.6) at 3 years, and 24.7% (95%CI: 19.5–31.0) at 4 years (Figure 2).

In particular, 35 of the 382 women switched from AIs to tamoxifen. Among continuous users of AI treatment, 93.5% (n = 357) had more than 80% of days covered (Table 1).

Determinants of non-persistence to AI

To study determinants of non-persistence to AI therapy, we excluded another 33 women who had no data collected in first face-to-face interview and 18 who discontinued their treatment or were censored before first face-to-face interview (Figure 1). We conducted the analysis after restricting our sample to women who reported they were taking their medication without outside help. Determinants of treatment discontinuation were thus studied for 292 women. Furthermore, CAM was found to be used only by women between 65 to 75 years old. Thus, the multivariate analysis

Figure 1. Study sample selection – ELIPPSE 65 cohort.
doi:10.1371/journal.pone.0081677.g001
was conducted among the 233 women whose age was lower than 75.

Patients’ characteristics are described in Table 2 for this sample of 233 women. At the time of diagnosis, women’s mean age was 71.8 (sd: 4.2). Stage 1 of BC was diagnosed in 69.1% of women (n = 161), stage 2 in 24.0% (n = 56) and stage 3 in 5.2% (n = 12). With respect to geriatric assessment, most women did not present any cognitive impairment as defined by the mini-COG questionnaire. Comorbidities were reported by 50.6% of women (n = 118). More than 3 different types of medication were received by almost half of the women (49.8%). A mere 13.7% of women reported having been involved in the decision to take hormonal therapy.

In the univariate analysis, we found that cancer characteristics were not associated with persistence to treatment. Polypharmacy decreased the risk of AI therapy discontinuation (Hazard Ratio, HR = 0.5; 95%CI: 0.2–1.0). Conversely, the use of CAM for BC treatment increased the risk of treatment discontinuation (HR = 3.1; 95%CI: 1.5–6.7).

In the multivariate analysis (Table 3), CAM use (HR = 3.2; 95%CI: 1.5–6.9), presence of comorbidities (HR = 2.2; 95%CI: 1.0–4.8) and absence of polypharmacy (HR = 0.4; 95%CI: 0.2–0.9) were independent predictors of treatment discontinuation.

Self-reports of non-adherence measured in patient questionnaire

Of the 292 women who were on treatment upon taking the questionnaire, 7 (2.4%) reported that they did not receive any hormonal therapy. When specifying medication names, 29 (9.9%) declared that they did not receive any anastrozole, letrozole or exemestane treatment. This was not found to be associated with treatment discontinuation.

![Figure 2. Curves corresponding to cumulative probability of aromatase inhibitor discontinuation with 95% confidence interval (dotted lines) — medication gaps longer than 3 months — ELIPPSE 65 cohort – n = 382.](doi:10.1371/journal.pone.0081677.g002)

| Time period | Entire follow-up | 1st year | 2nd year* | 3rd year** | 4th year*** |
|-------------|------------------|----------|-----------|------------|------------|
| n           | 382              | 382      | 310       | 256        | 162        |
| Mean MPR (SD) | 95.0 (8.6)   | 96.8 (8.3) | 96.9 (6.5) | 96.6 (5.8) | 97.2 (4.4) |
| >= 80% of days covered n(%) | 357 (93.5) | 365 (95.5) | 300 (96.8) | 249 (97.3) | 161 (99.4) |

*Medication Possession Ratio.
*Calculated for women with more than one year of treatment.
**Calculated for women with more than two years of treatment.
***Calculated for women with more than three years of treatment.

doi:10.1371/journal.pone.0081677.t001

Table 1. Treatment coverage according to duration of treatment in the ELIPPSE 65 cohort – n = 382.
Table 2. Population characteristics and factors associated with aromatase-inhibitors discontinuation in the ELIPPSE 65 cohort of women aged 74 or less – n = 233.

|                                | n (%) | Crude HR* [95% CI] | p-value |
|--------------------------------|-------|--------------------|---------|
| **Socio-demographic characteristics at diagnosis** |       |                    |         |
| Level of education             |       |                    |         |
| Less than high school certificate | 154 (66.1) | 1 | 0.39 |
| High school certificate or higher | 77 (33.0) | 1.38 [0.66–2.87] |         |
| Missing value                   | 2 (0.9) | -                  |         |
| Former occupation              |       |                    | 0.65    |
| Farmer, craftswoman, or business owner | 12 (5.1) | 1 |         |
| Executive manager              | 88 (37.8) | 0.46 [0.12–1.66] |         |
| Manual worker or employee       | 104 (44.6) | 0.46 [0.13–1.62] |         |
| Housewife                       | 23 (9.9) | 0.67 [0.15–2.99] |         |
| Unknown                         | 6 (2.6) | -                  |         |
| **Medical and treatment-related characteristics** |       |                    |         |
| PTNM stage                      |       |                    | 0.95    |
| I                              | 161 (69.1) | 1 |         |
| II                             | 56 (24.0) | 1.11 [0.47–2.61] |         |
| III                            | 12 (5.2) | 0.84 [0.11–6.32] |         |
| Missing value                   | 4 (1.7) | -                  |         |
| Breast surgery                  |       |                    |         |
| Breast conserving surgery       | 195 (85.5) | 1 |         |
| Mastectomy                      | 33 (14.5) | 1.03 [0.36–2.95] | 0.96    |
| Chemotherapy                    |       |                    |         |
| No                             | 169 (72.5) | 1 |         |
| Yes                            | 64 (27.5) | 0.64 [0.24–1.69] | 0.35    |
| Radiotherapy                    |       |                    |         |
| No                             | 7 (3.0) | 1                  |         |
| Yes                            | 226 (97.0) | 0.49 [0.11–2.07] | 0.38    |
| Self-reported co-morbidities   |       |                    |         |
| No                             | 115 (49.4) | 1 |         |
| Yes                            | 118 (50.6) | 1.59 [0.76–3.35] | 0.21    |
| Polypharmacy (> = 4 types of medications) |       |                    |         |
| No                             | 117 (50.2) | 1 |         |
| Yes                            | 116 (49.8) | 0.48 [0.22–0.98] | 0.05    |
| Use of complementary and alternative medicine for breast cancer care |       |                    |         |
| No                             | 196 (84.1) | 1 |         |
| Yes                            | 37 (15.9) | 3.11 [1.45–6.65] | 0.01    |
| **Psychosocial characteristics** |       |                    |         |
| Clear and sufficient information about disease provided at diagnosis |       |                    |         |
| No                             | 7 (3.0) | -                  |         |
| Yes                            | 226 (97.0) | - |         |
| Involvement in the decision to take hormonal therapy |       |                    |         |
| No                             | 201 (86.3) | 1 |         |
| Yes                            | 32 (13.7) | 0.98 [0.34–2.80] | 0.96    |
| **Geriatric assessment at 10 months** |       |                    |         |
| ADL disability                  |       |                    |         |
| Yes                            | 20 (8.6) | 1                  |         |
| No                             | 213 (91.4) | 1.06 [0.32–3.46] | 0.93    |
Among the 37 women (10.7%) who reported having forgotten to take their hormonal treatment at least once, the most frequent reason mentioned (29.7%) was not being at home when supposed to take the treatment. Another 9 women (3.0%) declared that they voluntarily interrupted their treatment in the 30 days prior to taking the questionnaire: 2 felt that the treatment was ineffective; 2 declared that they felt better; 2 suffered from side effects; 5 feared suffering from side effects; and 1 did not take the treatment because she was ill that day.

Discussion

AI treatment was prematurely discontinued by a large proportion of the women under study. Elderly women using complementary or alternative medicine or suffering from comorbidities were more likely to discontinue their treatment, whereas women with polypharmacy were less likely to discontinue.

We have recently conducted a metaregression analysis that synthesizes the available data on adherence to hormonal therapy in BC [15], based on 29 observational studies selected from a comprehensive qualitative review [14]. Taking into account duration and as well as study methodology, we have shown non-persistence to AI increased from 11.7% at 1 year to 31.3 at 5 year. Rates of non-persistence reported in this metagression match closely treatment discontinuation rates in this study. The wide variability of previously reported rates of treatment discontinuation, ranging from a low of 6% to a high of 40% at one year [13,26,27,28,29,30,31] is mostly due the data source used in the studies. The source of data has indeed been reported to explain over 68% of the variation in measures observed between studies [15].

Studies show that CAM is often used by cancer patients [32]. The prevalence of CAM use has been reported to reach 17% in older patient [33]. Little data is available for France, yet CAM also appears to be widely used in the country [34]. CAM use presents two problems. First, in other diseases such as AIDS, studies have shown that CAM use reduces treatment adherence [35,36]. Owen-Smith et al. [37] reported that HIV-positive women using CAM are 1.69 times more likely not to adhere to their treatment as compared to non-CAM users. Second, there are possible drug interactions between CAM and cancer therapies. In a previous study on cancer patients in France, Thomas-Schoemann et al. reported that most CAM used corresponded to anti-oxydants that could possibly generate drug interactions [34]. This is a particular concern for older patients, who are at increased risk of drug interactions notably due to polypharmacy. In our study, over 50% of patients received four or more types of medication, which put them at high risk of drug interaction. Physicians should pay attention to these two points, as CAM use is disclosed by patients to MDs in only 20% to 40% of cases [34,38]. Further studies are needed to evaluate more precisely the impact of CAM use on adherence in cancer patients, and to improve patient-physician communication on this topic.

As was previously reported for tamoxifen or other treatments in elderly populations [39,40], polypharmacy was found to be associated with increased adherence to treatment in our study. Adherence may be higher due to the development of daily routines among patients who have complex prescription regimens. However, Neugut et al. [30] found the opposite association. These conflicting results may be explained by differences in health care systems and medication insurance schemes. In the study by Neugut et al., cost issues associated with AI treatment predicted

---

**Table 2. Cont.**

|                        | n (%)     | Crude HR* | p-value (95% CI) |
|------------------------|-----------|-----------|------------------|
| Cognitive impairment   |           |           |                  |
| Yes                    | 46 (19.7) | 1         |                  |
| No                     | 187 (80.3)| 0.61 [0.21–1.75] | 0.33 |
| Unknown                | 3 (1.3)   | -         |                  |
| Mild or severe         |           |           |                  |
| depressive symptoms    |           |           |                  |
| Yes                    | 34 (14.6) | 1         |                  |
| No                     | 196 (84.1)| 0.77 [0.29–2.01] | 0.60 |
| Unknown                | 3 (1.3)   | -         |                  |

*Hazard Ratio.
doi:10.1371/journal.pone.0081677.t002

**Table 3. Independent factors associated with aromatase inhibitor intake discontinuation women aged 74 or less – n = 233.**

|                                      | n (%)     | Adjusted HR* | p-value (95% CI) |
|--------------------------------------|-----------|--------------|------------------|
| Complementary and alternative medicine for breast cancer care |           |              |                  |
| No                                   | 196 (84.1)| 1            |                  |
| Yes                                  | 37 (15.9) | 3.20 [1.49–6.86] | 0.00 |
| Self-reported co-morbidities         |           |              |                  |
| No                                   | 115 (49.4)| 1            |                  |
| Yes                                  | 118 (50.6)| 2.22 [1.03–4.78] | 0.04 |
| Polypharmacy (> = 4 types of medications) |           |              |                  |
| No                                   | 117 (50.2)| 1            |                  |
| Yes                                  | 116 (49.8)| 0.40 [0.18–0.88] | 0.02 |

*Hazard ratio – calculated in a Cox proportional hazard model.
doi:10.1371/journal.pone.0081677.t003
lower rates of persistence [30]. When patients’ insurance schemes do not provide full drug coverage, higher pill burdens lead to higher co-payments. In France, BC patients receive their treatment free of charge; hence polypharmacy was not associated with higher co-payments. In France, BC patients receive their medications from a pharmacy network, which does not necessarily have a central database, making it difficult to measure real adherence or persistence to medication. Accurate measures of adherence can nonetheless be obtained by using prescription refill rates in a closed pharmacy system such as the French one [22,41]. Measuring adherence in this way is not equivalent to measuring what the patient actually ingests, but it limits distortions caused by memory bias or by the desire to give socially acceptable answers [42]. Second, we were not able to measure in an unbiased manner the association between side effects and treatment discontinuation. Since side effects were evaluated at 10 months and at 2 years after diagnosis whereas prescription refills were evaluated continuously, the inclusion of a ‘side effects’ variable in our statistical model would have created a spurious association between increased side effects and increased adherence might have appeared in the analysis. The use of a time-dependent model was limited by the lack of variability over time of the ‘side effects’ variable, which was measured only twice at a fixed point in time.

Some elderly patients may be using CAM not as a complementary treatment, but as an alternative to conventional medicine. Health care providers need to be aware of CAM use among their patients, and of its possible impact on adherence to prescribed medication. As only a minority of patients spontaneously disclose CAM use to their physician, an open discussion between health care providers and patients is required to assess CAM use, discuss alternatives and emphasize that CAM should not replace anti-hormonal treatment. The saying “tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors” should be repeated continuously. Improving patient-physician communication on CAM use may improve hormonal therapy adherence.

Acknowledgments

We would like to thank both the women who agreed to participate in this study and their physicians for the time they devoted to medical data collection. We would also like to thank the physicians and technicians in the different insurance schemes who contributed to patient selection and data extraction (Direction Régionale du Service Medical PACA, Caisse Maladie Régionale Côte-d’Azur, Caisse Maladie Régionale Provence Overseas, Caisse Maladie Régionale Corse, Caisse des professions libérales Provence, Caisse Nationale Militaire de Sécurité Sociale, l’ensemble des Caisses locales d’Assurance Maladie de la Mutualité Sociale Agricole des Régions Provence-Alpes-Côtes d’Azur et Corse.)

We are indebted to Ariane Dorval for proofreading the English manuscript.

Author Contributions

Conceived and designed the experiments: LH ADB F. Rousseau F. Retornaz MM MKB PV RG. Performed the experiments: ADB DR MKB. Analyzed the data: LH ADB RG. Wrote the paper: LH ADB DR RG. Revised manuscript: LH ADB F. Rousseau F. Retornaz MM MKB PV RG.

References

1. Partridge AH, Avorn J, Wang P, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94: 632–661.
2. Rudd K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59: 56–66.
3. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on 10-year survival: an overview of the randomised trials. Lancet 365: 1687–1717.
4. Coombers RC, Hall E, Gibson LJ, Paridaens R, Jassem J, et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092.
5. Forbes JF, Cuzick J, Buzzard A, Howell A, Tobias JS, et al. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45–53.
6. Goss PE, Ingle JN, Martinis S, Robert NJ, Muss HB, et al. (2005) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 352: 1793–1802.
7. Howell A, Cuzick J, Baum M, Burzard A, Dowsett M, et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60–62.
8. Crivellari D, Sun Z, Coates AS, Price KN, Thrulimmann B, et al. (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26: 1972–1979.
9. Burstein HJ, Press MF, Aridell J, Anderson H, Buchholz TA, et al. (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3784–3796.
10. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thrulimmann B, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319–1329.
11. Dezentje V, Van Bljverkne J, Gelderblom H, Putter H, Van Herk - Sulke MP, et al. (2008) Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. J Clin Oncol 27: 1158s-1163s.
12. McGowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, et al. (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99: 1763–1769.
13. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, et al. (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126: 529–537.
14. Murphy CC, Bartholomew LP, Carpentier MY, Bluthmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134: 459–478.
15. Huiart L, Ferdynan C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138: 325–328.
16. Huiart L, Bouthik AD, Rey D, Tarpin C, Cluze C, et al. (2012) Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? Eur J Cancer 48: 1939–1946.
17. Martin-Latry K, Begaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiology and drug safety 19: 256–265.
18. Kast S (1983) Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31: 721–727.
19. Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36: 428–434.
20. Borson S, Scanlan J, Brush M, Valiantano P, Dokmak A (2000) The mini-cog: a cognitive ‘vital signs’ measure for dementia screening in multi-lingual elderly. Int J Geriatri Psychiatry 15: 1021–1027.
21. Almeida OP, Almeida SA (1999) Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatri Psychiatry 14: 830–836.
22. Andrade SE, Kahler KH, Frech F, Chan KA (2000) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15: 563–574; discussion 575-567.
23. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, et al. (2008) Medication compliance and persistence: terminology and definitions. Value Health 11: 44–47.
24. Fisher B, Costantino J, Redmond C, Piss JH, Bowman D, et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479–491.
25. Love RR (1990) Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82: 18–21.
26. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, et al. (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26: 556–562.
27. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, et al. (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20: 431–436.
28. Hershman DL, Kushi LH, Shao T, Buono D, Fillenbaum GA, et al. (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28: 4120–4126.
29. Huu L, Dell’Aniello S, Saisa S (2011) Use of tamoxifen and aromatase inhibitors in a large, population-based cohort of women with breast cancer. Br J Cancer 104: 1538–1563.
30. Neugut AJ, Subar M, Wilde ET, Stratton S, Brouse CH, et al. (2011) Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29: 2534–2542.
31. Neelhybod L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130: 681–689.
32. Richardson MA, Sanders T, Palmier JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18: 2505–2514.
33. Maggiore RJ, Gross CP, Togawa K, Tew WP, Mohile SG, et al. (2012) Use of complementary medications among older adults with cancer. Cancer 118: 4815–4823.
34. Thomas-Schoenmann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, et al. (2011) Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study]. Bull Cancer 98: 645–655.
35. Jernowall N, Zee MC, Reisen CA, Poppen PJ (2005) Complementary and alternative medicine and adherence to care among HIV-positive Latino gay and bisexual men. AIDS Care 17: 601–609.
36. Knippe HM, Wess J (2000) Use of alternative medicine in a sample of HIV-positive gay men: an exploratory study of prevalence and user characteristics. AIDS Care 12: 435–446.
37. Owen-Smith A, Dieleman R, Wengood G (2007) Complementary and alternative medicine use decreases adherence to HAART in HIV-positive women. AIDS Care 19: 589–593.
38. Eriembarg DM, Krosler RC; Van Rompay MI, Kaptchuck TJ, Wilkey SA, et al. (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135: 344–351.
39. Lash TL, Fox MP, Westrup JL, Fink AK, Sillman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99: 215–220.
40. Balkrishnan R (1998) Predictors of medication adherence in the elderly. Clin Ther 20: 764–771.
41. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487–497.
42. Choo PW, Rand CS, Inui TS, Lee ML, Cai E, et al. (1999) Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Medical care 37: 846–857.